Melbourne, Australia; 21 July 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the signing of an exclusive license and supply agreement with Shenyang Sky and Land Latex Co. Ltd. (Sky and Land) for the manufacture and sale of VivaGel^® condoms to the Government segment of the Chinese condom market. 

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2016.

Melbourne, Australia; 25 May 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that Starpharma’s DEP™ cabazitaxel eliminated neutropenia typical of cabazitaxel (Jevtana^®) in a preclinical study. 

The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio. 

Go to the article (external link)

Starpharma is presenting today at The CEO Session Series event in Sydney.

Starpharma and Ansell today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect™ VivaGel^® condoms for the upcoming Olympic Games in Rio de Janeiro.

Starpharma announced today that the VivaGel^® active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel^® condom.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2016.

In this issue:

> Message from the CEO

> Adama licenses Priostar^® for 2,4-D

> DEP^TM cabazitaxel shows superior performance

> Starpharma's Targeted DEP^TM conjugates - compelling results in an area of high interest

> AstraZeneca selects second DEP^TM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel^® BV in Australia and New Zealand

> MOU for VivaGel^® condom in China

> Half-year financial results

> Bio-Europe^® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

Starpharma today announced that it will present this week at the Bio-Europe^® conference in Stockholm. At the conference Starpharma will also be conducting partnering discussions with pharmaceutical companies for VivaGel^® BV, DEP^TM and other parts of Starpharma’s portfolio.